1238 related articles for article (PubMed ID: 33762954)
1. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Indari O; Jakhmola S; Manivannan E; Jha HC
Front Pharmacol; 2021; 12():632677. PubMed ID: 33762954
[TBL] [Abstract][Full Text] [Related]
2. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
4. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.
Dash P; Mohapatra S; Ghosh S; Nayak B
Front Pharmacol; 2020; 11():590154. PubMed ID: 33815095
[TBL] [Abstract][Full Text] [Related]
5. An Update on Current Therapeutic Drugs Treating COVID-19.
Wu R; Wang L; Kuo HD; Shannar A; Peter R; Chou PJ; Li S; Hudlikar R; Liu X; Liu Z; Poiani GJ; Amorosa L; Brunetti L; Kong AN
Curr Pharmacol Rep; 2020; 6(3):56-70. PubMed ID: 32395418
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs.
Chopra D; Boparai JK; Bhandari B; Srivastava A; Gupta R
Infect Disord Drug Targets; 2021; 21(7):e160921189260. PubMed ID: 33342420
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
Alam S; Kamal TB; Sarker MMR; Zhou JR; Rahman SMA; Mohamed IN
Front Pharmacol; 2021; 12():659577. PubMed ID: 34220503
[TBL] [Abstract][Full Text] [Related]
9. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
[TBL] [Abstract][Full Text] [Related]
10. Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.
Heustess AM; Allard MA; Thompson DK; Fasinu PS
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34071185
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena.
Samaddar A; Grover M; Nag VL
Front Pharmacol; 2020; 11():585888. PubMed ID: 33041830
[TBL] [Abstract][Full Text] [Related]
12. Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review.
Chakraborty D; Debnath F; Biswas S; Bhatta M; Ganguly S; Deb AK; Saha MK; Dutta S
J Clin Med Res; 2020 Aug; 12(8):463-471. PubMed ID: 32849934
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature.
Hershan AA
Saudi J Biol Sci; 2024 Jul; 31(7):104023. PubMed ID: 38799719
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies.
Singh VK; Chaurasia H; Mishra R; Srivastava R; Yadav AK; Dwivedi J; Singh P; Singh RK
Curr Pharm Des; 2022; 28(27):2211-2233. PubMed ID: 35909276
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
[TBL] [Abstract][Full Text] [Related]
16. Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted.
Borah P; Deb PK; Chandrasekaran B; Goyal M; Bansal M; Hussain S; Shinu P; Venugopala KN; Al-Shar'i NA; Deka S; Singh V
Front Mol Biosci; 2021; 8():627723. PubMed ID: 33681293
[TBL] [Abstract][Full Text] [Related]
17. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies.
Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
Front Pharmacol; 2021; 12():704205. PubMed ID: 34867318
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
19. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
20. [Umifenovir and coronavirus infections: a review of research results and clinical practice].
Leneva IA; Pshenichnaya NY; Bulgakova VA
Ter Arkh; 2020 Dec; 92(11):91-97. PubMed ID: 33720612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
